CD133 and Colorectal Cancer Survival
Author Information
Author(s): Horst D, Kriegl L, Engel J, Kirchner T, Jung A
Primary Institution: Ludwig-Maximilians-Universität München
Hypothesis
CD133 expression is an independent prognostic marker for low survival in colorectal cancer.
Conclusion
The study found that CD133 expression in colorectal cancer is significantly associated with lower patient survival rates.
Supporting Evidence
- CD133+ tumor cells were shown to correlate with worse survival outcomes in colorectal cancer patients.
- Patients with CD133-high tumors had a relative risk of 2.45 for worse survival compared to CD133-low tumors.
Takeaway
This study shows that a specific marker called CD133 can help doctors understand how likely patients with colon cancer are to survive.
Methodology
The study analyzed CD133+ tumor cells in colorectal cancer specimens using immunohistochemistry and correlated findings with patient survival data.
Limitations
The study excluded patients who died within 6 months after surgery, which may limit the generalizability of the findings.
Participant Demographics
Patients with moderately differentiated colorectal adenocarcinomas who underwent curative surgical resection.
Statistical Information
P-Value
0.002
Confidence Interval
1.18–5.13
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website